UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 15

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

001-40869
Commission File Number
 
THESEUS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
 
314 Main Street
Cambridge, Massachusetts 02142
(857) 400-9491
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
 
Common Stock, $0.0001 par value per share
(Title of each class of securities covered by this Form)
 
None
(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:


 Rule 12g-4(a)(1)
☒

Rule 12g-4(a)(2)
☐

Rule 12h-3(b)(1)(i)
☒

Rule 12h-3(b)(1)(ii) Rule 15d-6
☐

Rule 15d-22(b)
☐

Approximate number of holders of record as of the certification or notice date:
One

Pursuant to the requirements of the Securities Exchange Act of 1934, Theseus Pharmaceuticals, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

Date: February 26, 2024
THESEUS PHARMACEUTICALS, INC.
     
 
By:
 /s/ Michael Hearne
   
Name: Michael Hearne
   
Title: Chief Financial Officer


Theseus Pharmaceuticals (NASDAQ:THRX)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more Theseus Pharmaceuticals Charts.
Theseus Pharmaceuticals (NASDAQ:THRX)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more Theseus Pharmaceuticals Charts.